New guideline on treating COVID-19

29-Apr-2020 1:35 PM EDT, by McMaster University



Newswise — OTTAWA – An international team of physicians, pharmacists, medical researchers and patient partners has developed a clinical guideline for the treatment of patients with coronavirus disease 2019 (COVID-19), published in CMAJ (Canadian Medical Association Journal)VIEW ARTICLE

"The enormity of the adverse health consequences of COVID-19 has understandably left clinicians and patients eager for interventions that can decrease progression, prevent mortality and speed recovery," writes Dr. Gordon Guyatt, McMaster University, Hamilton, Ontario, and his coauthors. "This eagerness has perhaps contributed to overly sanguine assessments from experts, regulatory authorities and prominent politicians regarding the potential benefits of treatments, with underappreciation of potential harms."

The guideline, aimed at physicians and their patients, is based on the most recent available evidence as of April 25, 2020. It looks at treatments for patients with nonsevere and severe COVID-19. This comprehensive look at the quality of evidence found only low or very low-quality evidence supporting treatment benefit.

"As a result, the guideline panel made almost exclusively weak (conditional) recommendations against use of these agents in COVID-19 patients," says Dr. Guyatt.


  • Weak recommendation in favour of using corticosteroids in patients with severe COVID-19 and acute respiratory distress syndrome (ARDS)
  • Weak recommendation against using corticosteroids in patients with COVID-19 but without ARDS
  • Weak recommendation against using convalescent plasma in patients with severe COVID-19
  • Weak recommendation against using several antiviral drugs currently under consideration for treatment in patients with severe and nonsevere COVID-19.

The authors caution that two very low-quality studies have raised the possibility that hydroxychloroquine could increase the risk of mechanical ventilation and death.

"The recommendations in this guideline should discourage use of interventions for which there is very low-quality evidence, thus decreasing medical waste. However, misleading statements about and advocacy for use of medications for which we were unable to find robust evidence of benefit at this time present the major barriers to this guideline's implementation," conclude the authors.

An international team of physicians, pharmacists and researchers from Canada, China, South Korea, Mexico, Saudi Arabia and Singapore, as well as two patient partners, created the guideline.

It will be available in various user-friendly formats for clinicians as well as patients on the MAGICApp and at

"Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline" is published April 29, 2020.

Please credit CMAJ, not the Canadian Medical Association (CMA). CMAJ is an independent medical journal; views expressed do not necessarily reflect those of its owner, Joule Inc., a CMA company, or CMA.



Filters close

Showing results

110 of 4146
Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

access_time Embargo lifts in 2 days
Embargo will expire: 30-Nov-2020 10:00 AM EST Released to reporters: 24-Nov-2020 5:35 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 30-Nov-2020 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Showing results

110 of 4146